Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab initiation. A complete workup for causes of hepatitis and hypereosinophilia was negative, and liver biopsy showed signs compatible with drug-induced liver injury. After the withdrawal of vedolizumab, the patient's eosinophil count and liver enzymes normalized. As vedolizumab becomes more prominent, it is important to understand the potential side-effect profile of vedolizumab.
2 April 2025 in Journal of the Canadian Association of Gastroenterology
Background/Aims: Among Crohn’s disease patients with loss of response or non-response to ustekinumab (UST), there remains no clear strategy for dose escalation. Moreover, clinical associations and the role of therapeutic drug monitoring (TDM) are poorly understood. This study assessed response to escalation of UST therapy via increased dosing frequency or re-induction, as well as assessed associations of response. Methods: A single-centre retrospective cohort study was performed. Adults who underwent dose escalation to every 4 weeks or reinduction of UST were included. The primary outcome was clinical and biochemical remission which was defined as a Harvey Bradshaw Index (HBI) of <5 and a C-reactive protein (CRP) level within the normal limit or a Fecal Calprotectin (FCP) level <250 ug/g. Partial response to treatment was defined as a 50% decrease from baseline HBI, CRP, or FCP. Results: Thirty-nine patients were included. Clinical outcomes were assessed at a median of 17 weeks (IQR 12-21). Clinical and biochemical remission was achieved in 30.8% of patients (n = 12). Remission was found to be more likely among patients with lower baseline HBI (5.2 vs 9.0 P = .044) and younger patients (29.8 years vs 37.7 P = .046). No association was observed between baseline TDM values in the remission vs the non-remission group (3.32 ug/mL vs 2.91 ug/mL p=0.77). No severe adverse events were recorded. Conclusion: UST dose escalation, in the form of reinduction or increased frequency to every 4 weeks may be effective among patients with loss of response or partial response, though predictors of response and strategy of escalation remain unclear.
18 February 2026 in Journal of the Canadian Association of Gastroenterology
Background: There is limited evidence to support optimal concentrations for therapeutic drug monitoring in patients with Crohn’s disease (CD) who experience a loss of response (LOR) to tumour necrosis factor antagonists. This study aimed to determine the threshold trough adalimumab concentration beyond which patients with LOR are unable to recapture a response after dose escalation. Methods: Enrolled patients had responded to adalimumab therapy after ≥16 weeks and subsequently experienced a secondary LOR, defined as a C-reactive protein (CRP) level ≥5 mg/L and/or a fecal calprotectin (FC) level ≥250 µg/g. Dosing was escalated from biweekly to weekly. Patients were then assessed for 12 weeks to determine their ability to recapture a response, defined as a CRP response (≥50% CRP decrease and/or CRP <5 mg/L) and/or FC response (≥50% FC decrease and/or FC <150 µg/g). The relationship between baseline trough concentration and non-recapture of biochemical response was evaluated using logistic regression. Results: Of 97 enrolled patients, 49 (50.5%) did not recapture a response to adalimumab after dose escalation. Baseline trough concentration was not associated with non-recapture of biochemical response (odds ratio, 0.98; 95% CI: 0.91-1.06; P = .626). There was no threshold trough concentration identified that was predictive of non-recapture of biochemical response. No new adalimumab safety signals were identified. Conclusions: No association was observed between trough adalimumab concentration and non-recapture of biochemical response after dose escalation for secondary LOR in CD. The threshold concentration above which dose escalation is ineffective remains unclear. ClinicalTrials.gov identifier: NCT02896985.